AAAAAA

   
Results: 1-25 | 26-50 | 51-75
Results: 26-50/75
PATIENT COMPLIANCE AND DRUG FAILURE IN PROTEASE INHIBITOR MONOTHERAPY
Authors: VANHOVE GF SCHAPIRO JM WINTERS MA MERIGAN TC BLASCHKE TF
Citation: Gf. Vanhove et al., PATIENT COMPLIANCE AND DRUG FAILURE IN PROTEASE INHIBITOR MONOTHERAPY, JAMA, the journal of the American Medical Association, 276(24), 1996, pp. 1955-1956
GENOTYPIC AND PHENOTYPIC CHANGES DURING CULTURE OF A MULTINUCLEOSIDE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 STRAIN IN THE PRESENCE AND ABSENCE OF ADDITIONAL REVERSE-TRANSCRIPTASE INHIBITORS
Authors: SHAFER RW WINTERS MA IVERSEN AKN MERIGAN TC
Citation: Rw. Shafer et al., GENOTYPIC AND PHENOTYPIC CHANGES DURING CULTURE OF A MULTINUCLEOSIDE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 STRAIN IN THE PRESENCE AND ABSENCE OF ADDITIONAL REVERSE-TRANSCRIPTASE INHIBITORS, Antimicrobial agents and chemotherapy, 40(12), 1996, pp. 2887-2890
A TRIAL COMPARING NUCLEOSIDE MONOTHERAPY WITH COMBINATION THERAPY IN HIV-INFECTED ADULTS WITH CD4 CELL COUNTS FROM 200 TO 500 PER CUBIC MILLIMETER
Authors: HAMMER SM KATZENSTEIN DA HUGHES MD GUNDACKER H SCHOOLEY RT HAUBRICH RH HENRY WK LEDERMAN MM PHAIR JP NIU M HIRSCH MS MERIGAN TC BLASCHKE TF SIMPSON D MCLAREN C ROONEY J SALGO M
Citation: Sm. Hammer et al., A TRIAL COMPARING NUCLEOSIDE MONOTHERAPY WITH COMBINATION THERAPY IN HIV-INFECTED ADULTS WITH CD4 CELL COUNTS FROM 200 TO 500 PER CUBIC MILLIMETER, The New England journal of medicine, 335(15), 1996, pp. 1081-1090
THE RELATION OF VIROLOGICAL AND IMMUNOLOGICAL MARKERS TO CLINICAL OUTCOMES AFTER NUCLEOSIDE THERAPY IN HIV-INFECTED ADULTS WITH 200 TO 500 CD4 CELLS PER CUBIC MILLIMETER
Authors: KATZENSTEIN DA HAMMER SM HUGHES MD GUNDACKER H JACKSON JB FISCUS S RASHEED S ELBEIK T REICHMAN R JAPOUR A MERIGAN TC HIRSCH MS
Citation: Da. Katzenstein et al., THE RELATION OF VIROLOGICAL AND IMMUNOLOGICAL MARKERS TO CLINICAL OUTCOMES AFTER NUCLEOSIDE THERAPY IN HIV-INFECTED ADULTS WITH 200 TO 500 CD4 CELLS PER CUBIC MILLIMETER, The New England journal of medicine, 335(15), 1996, pp. 1091-1098
TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION WITH SAQUINAVIR, ZIDOVUDINE, AND ZALCITABINE
Authors: COLLIER AC COOMBS RW SCHOENFELD DA BASSETT RL TIMPONE J BARUCH A JONES M FACEY K WHITACRE C MCAULIFFE VJ FRIEDMAN HM MERIGAN TC REICHMAN RC HOOPER C COREY L
Citation: Ac. Collier et al., TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION WITH SAQUINAVIR, ZIDOVUDINE, AND ZALCITABINE, The New England journal of medicine, 334(16), 1996, pp. 1011-1017
MULTIPLE CEREBRAL-LESIONS COMPLICATING THERAPY WITH INTERLEUKIN-2
Authors: KARP BI YANG JC KHORSAND M WOOD R MERIGAN TC
Citation: Bi. Karp et al., MULTIPLE CEREBRAL-LESIONS COMPLICATING THERAPY WITH INTERLEUKIN-2, Neurology, 47(2), 1996, pp. 417-424
THE LABORATORY IN MANAGING HIV-INFECTION
Authors: DWYER DE ADELSTEIN S CUNNINGHAM AL MERIGAN TC
Citation: De. Dwyer et al., THE LABORATORY IN MANAGING HIV-INFECTION, Medical journal of Australia, 164(5), 1996, pp. 301-303
MULTIDRUG-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 STRAINS RESULTING FROM COMBINATION ANTIRETROVIRAL THERAPY
Authors: IVERSEN AKN SHAFER RW WEHRLY K WINTERS MA MULLINS JI CHESEBRO B MERIGAN TC
Citation: Akn. Iversen et al., MULTIDRUG-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 STRAINS RESULTING FROM COMBINATION ANTIRETROVIRAL THERAPY, Journal of virology, 70(2), 1996, pp. 1086-1090
ZIDOVUDINE RESISTANCE REVERSE-TRANSCRIPTASE MUTATIONS DURING DIDANOSINE MONOTHERAPY
Authors: SHAFER RW WINTERS MA JELLINGER RM MERIGAN TC
Citation: Rw. Shafer et al., ZIDOVUDINE RESISTANCE REVERSE-TRANSCRIPTASE MUTATIONS DURING DIDANOSINE MONOTHERAPY, The Journal of infectious diseases, 174(2), 1996, pp. 448-449
A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE IMMUNOGENICITY OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) RGP160 VACCINE IN HIV-INFECTED SUBJECTS WITH GREATER-THAN-OR-EQUAL-TO-400 MM(3) CD4 T-LYMPHOCYTES (AIDS CLINICAL-TRIALS GROUP PROTOCOL-137)/
Authors: VALENTINE FT KUNDU S HASLETT PAJ KATZENSTEIN D BECKETT L SPINO C BORUCKI M VASQUEZ M SMITH G KORVICK J KAGAN J MERIGAN TC
Citation: Ft. Valentine et al., A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE IMMUNOGENICITY OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) RGP160 VACCINE IN HIV-INFECTED SUBJECTS WITH GREATER-THAN-OR-EQUAL-TO-400 MM(3) CD4 T-LYMPHOCYTES (AIDS CLINICAL-TRIALS GROUP PROTOCOL-137)/, The Journal of infectious diseases, 173(6), 1996, pp. 1336-1346
POLYETHYLENE GLYCOL-MODIFIED INTERLEUKIN-2 AND THYMOSIN ALPHA(1) IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
Authors: RAMACHANDRAN R KATZENSTEIN DA WINTERS MA KUNDU SK MERIGAN TC
Citation: R. Ramachandran et al., POLYETHYLENE GLYCOL-MODIFIED INTERLEUKIN-2 AND THYMOSIN ALPHA(1) IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION, The Journal of infectious diseases, 173(4), 1996, pp. 1005-1008
THE ASSOCIATION BETWEEN HIV PHENOTYPE, VIRUS BURDEN, CODON-215 MUTATION AND CD4 CELL DECLINE - REPLY
Authors: KOZAL MJ SHAFER RW WINTERS MA KATZENSTEIN DA HALPERN J MERIGAN TC
Citation: Mj. Kozal et al., THE ASSOCIATION BETWEEN HIV PHENOTYPE, VIRUS BURDEN, CODON-215 MUTATION AND CD4 CELL DECLINE - REPLY, Journal of acquired immune deficiency syndromes and human retrovirology, 9(1), 1995, pp. 101-102
DELAVIRDINE (DLV) SUSCEPTIBILITY OF HIV-1 ISOLATES OBTAINED FROM PATIENTS RECEIVING DLV MONOTHERAPY
Authors: DEMETER LM SHAFER RW PARA M MORSE G FREIMUTH W MERIGAN TC REICHMAN RC
Citation: Lm. Demeter et al., DELAVIRDINE (DLV) SUSCEPTIBILITY OF HIV-1 ISOLATES OBTAINED FROM PATIENTS RECEIVING DLV MONOTHERAPY, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 23-23
MUTATIONAL ANALYSIS OF THE SAQUINAVIR HIGH-DOSE MONOTHERAPY STUDY
Authors: SCHAPIRO JM WINTERS M MERIGAN TC
Citation: Jm. Schapiro et al., MUTATIONAL ANALYSIS OF THE SAQUINAVIR HIGH-DOSE MONOTHERAPY STUDY, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 73-73
NATURAL POLYMORPHISM OF HIV-1 CLADE-B PROTEASE GENE AND IMPLICATIONS FOR THERAPY
Authors: KOZAL MJ SHAH N YANG R SHEN N FUCINI R MERIGAN TC RICHMAN DD CHEE MS GINGERAS TR
Citation: Mj. Kozal et al., NATURAL POLYMORPHISM OF HIV-1 CLADE-B PROTEASE GENE AND IMPLICATIONS FOR THERAPY, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 76-76
SURROGATE MARKERS OF HIV - STRATEGIES AND ISSUES FOR SELECTION AND USE - PROCEEDINGS OF A SYMPOSIUM HELD IN ARLINGTON, VIRGINIA, OCTOBER 12-14, 1994 - INTRODUCTION
Authors: MERIGAN TC SCHOOLEY RT
Citation: Tc. Merigan et Rt. Schooley, SURROGATE MARKERS OF HIV - STRATEGIES AND ISSUES FOR SELECTION AND USE - PROCEEDINGS OF A SYMPOSIUM HELD IN ARLINGTON, VIRGINIA, OCTOBER 12-14, 1994 - INTRODUCTION, Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 5-5
INHIBITORS OF PROTEASE LOOK BETTER THAN THOSE OF REVERSE-TRANSCRIPTASE FOR HIV IN MAN
Authors: MERIGAN TC SCHAPIRO J
Citation: Tc. Merigan et J. Schapiro, INHIBITORS OF PROTEASE LOOK BETTER THAN THOSE OF REVERSE-TRANSCRIPTASE FOR HIV IN MAN, AIDS research and human retroviruses, 11, 1995, pp. 168-168
HUMAN CYTOMEGALOVIRUS (CMV) DNA IN PLASMA REFLECTS QUANTITY OF CMV DNA PRESENT IN LEUKOCYTES
Authors: ZIPETO D MORRIS S HONG C DOWLING A WOLITZ R MERIGAN TC RASMUSSEN L
Citation: D. Zipeto et al., HUMAN CYTOMEGALOVIRUS (CMV) DNA IN PLASMA REFLECTS QUANTITY OF CMV DNA PRESENT IN LEUKOCYTES, Journal of clinical microbiology, 33(10), 1995, pp. 2607-2611
QUANTITATIVE-ANALYSIS OF SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING VIRUS IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
Authors: SHAFER RW AGUINIGA E MERIGAN TC
Citation: Rw. Shafer et al., QUANTITATIVE-ANALYSIS OF SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING VIRUS IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1, Journal of clinical microbiology, 33(1), 1995, pp. 212-214
PROPHYLACTIC GANCICLOVIR TREATMENT REDUCES FUNGAL AS WELL AS CYTOMEGALOVIRUS INFECTIONS AFTER HEART-TRANSPLANTATION
Authors: WAGNER JA ROSS H HUNT S GAMBERG P VALANTINE H MERIGAN TC STINSON EB
Citation: Ja. Wagner et al., PROPHYLACTIC GANCICLOVIR TREATMENT REDUCES FUNGAL AS WELL AS CYTOMEGALOVIRUS INFECTIONS AFTER HEART-TRANSPLANTATION, Transplantation, 60(12), 1995, pp. 1473-1477
A QUARTER-CENTURY OF ANTIVIRAL THERAPY
Authors: MERIGAN TC
Citation: Tc. Merigan, A QUARTER-CENTURY OF ANTIVIRAL THERAPY, The New England journal of medicine, 333(25), 1995, pp. 1704-1705
PERSISTENCE OF ATTENUATED REV GENES IN A HUMAN-IMMUNODEFICIENCY-VIRUSTYPE 1-INFECTED ASYMPTOMATIC INDIVIDUAL
Authors: IVERSEN AKN SHPAER EG RODRIGO AG HIRSCH MS WALKER BD SHEPPARD HW MERIGAN TC MULLINS JI
Citation: Akn. Iversen et al., PERSISTENCE OF ATTENUATED REV GENES IN A HUMAN-IMMUNODEFICIENCY-VIRUSTYPE 1-INFECTED ASYMPTOMATIC INDIVIDUAL, Journal of virology, 69(9), 1995, pp. 5743-5753
DRUG-RESISTANCE AND HETEROGENEOUS LONG-TERM VIROLOGICAL RESPONSES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED SUBJECTS TO ZIDOVUDINE AND DIDANOSINE COMBINATION THERAPY
Authors: SHAFER RW IVERSEN AKN WINTERS MA AGUINIGA E KATZENSTEIN DA MERIGAN TC
Citation: Rw. Shafer et al., DRUG-RESISTANCE AND HETEROGENEOUS LONG-TERM VIROLOGICAL RESPONSES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED SUBJECTS TO ZIDOVUDINE AND DIDANOSINE COMBINATION THERAPY, The Journal of infectious diseases, 172(1), 1995, pp. 70-78
NEW VIROLOGICAL TOOLS FOR THE DESIGN AND ANALYSIS OF CLINICAL-TRIALS
Authors: SHAFER RW MERIGAN TC
Citation: Rw. Shafer et Tc. Merigan, NEW VIROLOGICAL TOOLS FOR THE DESIGN AND ANALYSIS OF CLINICAL-TRIALS, The Journal of infectious diseases, 171(5), 1995, pp. 1325-1328
CLARIFICATION OF A METHOD TO REVERSE TRANSCRIBE HUMAN-IMMUNODEFICIENCY-VIRUS RNA
Authors: KOZAL MJ SHAFER RW WINTERS MA KATZENSTEIN DA MERIGAN TC
Citation: Mj. Kozal et al., CLARIFICATION OF A METHOD TO REVERSE TRANSCRIBE HUMAN-IMMUNODEFICIENCY-VIRUS RNA, The Journal of infectious diseases, 171(4), 1995, pp. 1072-1072
Risultati: 1-25 | 26-50 | 51-75